<ul>
<li>通用電氣航空：卡塔爾交易推動數十億美元增長引擎</li>
</ul>
<p>通用電氣醫療科技（NASDAQ: GEHC）高管表示，儘管第一季度表現令人失望，導致全年指引下調，但公司對長期增長前景依然充滿信心，主要面臨的短期挑戰是通貨膨脹帶來的成本壓力。</p>
<p>在拉斯維加斯舉行的美國銀行證券醫療會議上，通用電氣醫療的副總裁兼首席財務官詹姆斯·薩卡羅表示，公司 “最終不得不下調年度指引”，他表示管理層對此 “非常重視”。他將下調歸因於公司需要在展望中反映的 “非常劇烈的通貨膨脹成本”。</p>
<ul>
<li>霍尼韋爾的拆分：HON 股票對投資者來説是個甜蜜的交易嗎？</li>
</ul>
<p>儘管如此，薩卡羅強調了幾個強勁的領域。他表示，第一季度訂單同比增長略超過 1%，而去年同期的比較為 10%，銷售額也達到了公司預期範圍的高端。他還表示，公司產品管道基本按計劃推進，通用電氣醫療在其心跳管理系統方面取得了進展。</p>
<h2>通貨膨脹和定價仍然是投資者關注的關鍵</h2>
<p>薩卡羅表示，通用電氣醫療的產品組合特別容易受到某些成本壓力的影響，因為其產品高度工程化，並且包括全球採購的組件。他提到貨運、物流、燃料、氦氣、稀土元素和內存芯片等領域的壓力。</p>
<ul>
<li>超聲波減肥：通用電氣醫療與諾和諾德的合作</li>
</ul>
<p>根據薩卡羅的説法，公司在貨運和物流成本方面遭受了約 1 億美元的影響，以及與中東衝突相關的約 5000 萬美元的其他成本。他還指出內存芯片的通貨膨脹，表示公司在該成本類別上看到了一億美元的增加。</p>
<p>薩卡羅表示，通用電氣醫療假設當前的內存芯片價格將持續到今年剩餘時間，並在其預測中建立了額外的緩衝和應急措施。他表示，公司已經鎖定了供應，並且迄今為止沒有看到內存供應的限制。</p>
<p>在定價方面，薩卡羅表示公司在重新定價積壓訂單方面能力有限，但在新訂單方面靈活性更大。他説：“我們目前的成本與之前相比發生了結構性變化”，並補充説通用電氣醫療在新業務決策中反映了這些更高的成本。</p>
<h2>資本配置包括回購、研發和併購</h2>
<p>薩卡羅表示，通用電氣醫療在第一季度以約 70 美元的價格回購了股票，採用基於折現現金流的內在價值模型。他表示，公司將回購視為其持續資本部署戰略的一部分，在對業務進行再投資和追求有針對性的收購之後。</p>
<p>他還提到在第一季度完成了 Intelerad 的收購，稱其在戰略和財務上都是增值的。薩卡羅表示，公司還繼續支付股息。</p>
<h2>業務結構和患者護理解決方案審查</h2>
<p>高級成像解決方案的總裁兼首席執行官菲利普·D·拉克利夫討論了公司將業務合併為高級成像解決方案的決定。他表示，客户正在向更橫向的護理連續體轉變，從初步掃描和病變檢測到診斷、規劃和治療。拉克利夫表示，通用電氣醫療看到利用數據和人工智能改善工作流程效率和患者結果的機會。</p>
<p>薩卡羅還提到了患者護理解決方案（PCS），表示該部門在第一季度表現令人失望，儘管基本符合預期。他表示，8% 的下降和業務報告的利潤水平 “不是可接受的表現閾值”。公司專注於改善業務，同時評估 “戰略選擇” 和 PCS 在通用電氣醫療中的角色。</p>
<p>薩卡羅表示，PCS 與公司其他業務的關聯性低於超聲波和成像，並將其描述為相對於新合併的成像業務和藥物診斷而言的低利潤業務。</p>
<h2>產品管道和成像前景</h2>
<p>拉克利夫表示，自公司分拆以來，通用電氣醫療超過 30 億美元的投資開始顯現成效。他表示，公司正進入一個在 CT、MR、超聲波和影像引導治療方面顯著產品創新的時期，預計在未來六到 18 個月內推出重要的新產品。</p>
<p>他將光子計數 CT 描述為一個 “藍海” 機會，而不僅僅是通用電氣醫療現有基礎的替代週期。拉克利夫表示，公司在光子計數 CT 方面的潛在管道 “遠超 1 億美元”，並預計在 2026 年下半年及 2027 年實現收入轉化。</p>
<p>薩卡羅表示，預計新產品將支持利潤改善，因為它們通常比前代產品價格更高、成本更低。他還提到通過心跳管理系統的精益運營改進和一般成本控制將有助於長期利潤機會。</p>
<h2>中國和 Flircado 的進展</h2>
<p>薩卡羅表示，通用電氣醫療在中國進行了變革，包括引入 Will Song 作為領導者，專注於商業執行、政府事務和市場細分。他表示，公司正在提高勝率，並看到更具建設性的經濟背景，儘管並未改變對中國市場下滑的預期。</p>
<p>拉克利夫表示，中國的情緒已經穩定，並指出通用電氣醫療在該國的大規模佈局，包括數千名員工和多個製造工廠。</p>
<p>薩卡羅還表示，Flircado 取得了進展，其年運行率從約 2500 萬美元上升到一個季度後大約 4600 萬美元。他重申公司在 2028 年前實現超過 5 億美元收入的目標，同時強調採用將謹慎管理，以確保客户獲得積極體驗。</p>
<p>他説公司正在處理報銷、放射藥學製造工作流程和客户現場採用等關鍵因素，以推動產品上市。</p>
<p>展望未來，薩卡羅表示，GE HealthCare 預計在今年剩餘時間內訂單增長將更高，並繼續瞄準中個位數的中期銷售增長。他表示，公司仍專注於創新和運營執行，同時應對波動的成本環境。</p>
<h2>關於 GE HealthCare Technologies NASDAQ: GEHC</h2>
<p>GE HealthCare Technologies NASDAQ: GEHC 是一家全球醫療技術和診斷公司，開發、製造和銷售廣泛的產品和服務，服務於醫療保健提供者。其產品組合以診斷成像系統為中心，包括 MRI、CT、PET 和 X 射線設備，以及超聲設備。該公司還提供患者監護和麻醉輸送系統、介入和外科成像解決方案，以及用於臨牀護理和研究環境的分子成像技術。</p>
<p>除了硬件，GE HealthCare 還提供軟件、分析和生命週期服務，旨在改善臨牀工作流程和設備正常運行時間。</p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 GE HealthCare Technologies 嗎？</h2>
<p>在考慮 GE HealthCare Technologies 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 GE HealthCare Technologies 並不在名單上。</p>
<p>雖然 GE HealthCare Technologies 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

GEHC

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

<p>GE HealthCare Technologies 儘管在第一季度遭遇挫折並因通脹壓力下調了全年指引，但仍對長期增長持樂觀態度。首席財務官 James Saccaro 強調訂單增長了 1% 和強勁的銷售，同時提到物流和內存芯片帶來的顯著成本影響。公司專注於資本配置，包括股票回購和研發，並預計在未來幾個月將有顯著的產品創新</p>

<ul>
<li>GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine</li>
</ul>
<div class="lb-trans"><ul>
<li>通用電氣航空：卡塔爾交易推動數十億美元增長引擎</li>
</ul>
</div><p>GE HealthCare Technologies NASDAQ: GEHC executives said the company remains confident in its long-term growth prospects despite a disappointing first quarter that led to a reduction in full-year guidance, citing inflationary cost pressures as the primary near-term challenge.</p>
<div class="lb-trans"><p>通用電氣醫療科技（NASDAQ: GEHC）高管表示，儘管第一季度表現令人失望，導致全年指引下調，但公司對長期增長前景依然充滿信心，主要面臨的短期挑戰是通貨膨脹帶來的成本壓力。</p>
</div><p>Speaking at a Bank of America Securities healthcare conference in Las Vegas, James Saccaro, GE HealthCare’s vice president and chief financial officer, said the company “ended up having to lower guidance for the year,” a move he said management takes “very seriously.” He attributed the reduction to “very dramatic inflationary costs” that the company needed to reflect in its outlook.</p>
<div class="lb-trans"><p>在拉斯維加斯舉行的美國銀行證券醫療會議上，通用電氣醫療的副總裁兼首席財務官詹姆斯·薩卡羅表示，公司 “最終不得不下調年度指引”，他表示管理層對此 “非常重視”。他將下調歸因於公司需要在展望中反映的 “非常劇烈的通貨膨脹成本”。</p>
</div><ul>
<li>Honeywell’s Breakup: Is HON Stock a Sweet Deal for Investors?</li>
</ul>
<div class="lb-trans"><ul>
<li>霍尼韋爾的拆分：HON 股票對投資者來説是個甜蜜的交易嗎？</li>
</ul>
</div><p>Even so, Saccaro highlighted several areas of strength. He said first-quarter orders grew a little over 1% against a 10% comparison from the prior year, while sales came in at the high end of the company’s expected range. He also said the company’s product pipeline is largely on track and that GE HealthCare has made progress with its Heartbeat management system.</p>
<div class="lb-trans"><p>儘管如此，薩卡羅強調了幾個強勁的領域。他表示，第一季度訂單同比增長略超過 1%，而去年同期的比較為 10%，銷售額也達到了公司預期範圍的高端。他還表示，公司產品管道基本按計劃推進，通用電氣醫療在其心跳管理系統方面取得了進展。</p>
</div><h2>Inflation and Pricing Remain Key Investor Focus</h2>
<div class="lb-trans"><h2>通貨膨脹和定價仍然是投資者關注的關鍵</h2>
</div><p>Saccaro said GE HealthCare’s portfolio is particularly exposed to certain cost pressures because its products are highly engineered and include components sourced globally. He cited freight, logistics, fuel, helium, rare earth elements and memory chips as areas of pressure.</p>
<div class="lb-trans"><p>薩卡羅表示，通用電氣醫療的產品組合特別容易受到某些成本壓力的影響，因為其產品高度工程化，並且包括全球採購的組件。他提到貨運、物流、燃料、氦氣、稀土元素和內存芯片等領域的壓力。</p>
</div><ul>
<li>Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play</li>
</ul>
<div class="lb-trans"><ul>
<li>超聲波減肥：通用電氣醫療與諾和諾德的合作</li>
</ul>
</div><p>According to Saccaro, the company saw about $100 million of impact from freight and logistics costs, along with about $50 million in other costs tied to the Middle East conflict. He also pointed to memory chip inflation, saying the company had seen a $100 million increase in that cost category.</p>
<div class="lb-trans"><p>根據薩卡羅的説法，公司在貨運和物流成本方面遭受了約 1 億美元的影響，以及與中東衝突相關的約 5000 萬美元的其他成本。他還指出內存芯片的通貨膨脹，表示公司在該成本類別上看到了一億美元的增加。</p>
</div><p>Saccaro said GE HealthCare has assumed current memory chip prices continue through the rest of the year, with additional buffers and contingencies built into its forecast. He said the company has supply locked in and has not seen memory supply constraints to date.</p>
<div class="lb-trans"><p>薩卡羅表示，通用電氣醫療假設當前的內存芯片價格將持續到今年剩餘時間，並在其預測中建立了額外的緩衝和應急措施。他表示，公司已經鎖定了供應，並且迄今為止沒有看到內存供應的限制。</p>
</div><p>On pricing, Saccaro said the company has limited ability to reprice backlog, but greater flexibility on new orders. “Our costs at this moment in time have structurally changed versus prior,” he said, adding that GE HealthCare is reflecting those higher costs in decisions on new business.</p>
<div class="lb-trans"><p>在定價方面，薩卡羅表示公司在重新定價積壓訂單方面能力有限，但在新訂單方面靈活性更大。他説：“我們目前的成本與之前相比發生了結構性變化”，並補充説通用電氣醫療在新業務決策中反映了這些更高的成本。</p>
</div><h2>Capital Allocation Includes Buybacks, R&amp;D and M&amp;A</h2>
<div class="lb-trans"><h2>資本配置包括回購、研發和併購</h2>
</div><p>Saccaro said GE HealthCare repurchased shares in the first quarter at around $70, using an intrinsic value model based on discounted cash flow. He said the company views buybacks as part of its ongoing capital deployment strategy, after reinvesting in the business and pursuing targeted acquisitions.</p>
<div class="lb-trans"><p>薩卡羅表示，通用電氣醫療在第一季度以約 70 美元的價格回購了股票，採用基於折現現金流的內在價值模型。他表示，公司將回購視為其持續資本部署戰略的一部分，在對業務進行再投資和追求有針對性的收購之後。</p>
</div><p>He also pointed to the closing of Intelerad in the first quarter, describing it as strategically and financially accretive. Saccaro said the company also continues to pay a dividend.</p>
<div class="lb-trans"><p>他還提到在第一季度完成了 Intelerad 的收購，稱其在戰略和財務上都是增值的。薩卡羅表示，公司還繼續支付股息。</p>
</div><h2>Business Structure and PCS Review</h2>
<div class="lb-trans"><h2>業務結構和患者護理解決方案審查</h2>
</div><p>Philip D. Rackliffe, president and CEO of Advanced Imaging Solutions, discussed the company’s decision to combine businesses into Advanced Imaging Solutions. He said customers are moving toward a more horizontal care continuum, from initial scans and lesion detection through diagnosis, planning and therapy. Rackliffe said GE HealthCare sees an opportunity to use data and AI to improve workflow efficiency and patient outcomes.</p>
<div class="lb-trans"><p>高級成像解決方案的總裁兼首席執行官菲利普·D·拉克利夫討論了公司將業務合併為高級成像解決方案的決定。他表示，客户正在向更橫向的護理連續體轉變，從初步掃描和病變檢測到診斷、規劃和治療。拉克利夫表示，通用電氣醫療看到利用數據和人工智能改善工作流程效率和患者結果的機會。</p>
</div><p>Saccaro also addressed Patient Care Solutions, or PCS, saying the segment had a disappointing first quarter, though largely in line with expectations. He said an 8% decline and the margin level reported by the business were “not an acceptable threshold of performance.” The company is focused on improving the business, while also evaluating “strategic alternatives” and the role PCS plays within GE HealthCare.</p>
<div class="lb-trans"><p>薩卡羅還提到了患者護理解決方案（PCS），表示該部門在第一季度表現令人失望，儘管基本符合預期。他表示，8% 的下降和業務報告的利潤水平 “不是可接受的表現閾值”。公司專注於改善業務，同時評估 “戰略選擇” 和 PCS 在通用電氣醫療中的角色。</p>
</div><p>Saccaro said PCS is less linked to the company’s other businesses than ultrasound and imaging, and described it as a lower-margin business relative to the newly combined imaging business and Pharmaceutical Diagnostics.</p>
<div class="lb-trans"><p>薩卡羅表示，PCS 與公司其他業務的關聯性低於超聲波和成像，並將其描述為相對於新合併的成像業務和藥物診斷而言的低利潤業務。</p>
</div><h2>Product Pipeline and Imaging Outlook</h2>
<div class="lb-trans"><h2>產品管道和成像前景</h2>
</div><p>Rackliffe said GE HealthCare’s more than $3 billion of investment since its spin-off is beginning to show results. He said the company is entering a period of significant product innovation across CT, MR, ultrasound and image-guided therapies, with material new products expected over the next six to 18 months.</p>
<div class="lb-trans"><p>拉克利夫表示，自公司分拆以來，通用電氣醫療超過 30 億美元的投資開始顯現成效。他表示，公司正進入一個在 CT、MR、超聲波和影像引導治療方面顯著產品創新的時期，預計在未來六到 18 個月內推出重要的新產品。</p>
</div><p>He described photon counting CT as a “blue ocean” opportunity rather than primarily a replacement cycle for GE HealthCare’s installed base. Rackliffe said the company had a potential funnel “well in excess of $100 million” for photon counting CT and expects revenue conversion in the back half of 2026 and into 2027.</p>
<div class="lb-trans"><p>他將光子計數 CT 描述為一個 “藍海” 機會，而不僅僅是通用電氣醫療現有基礎的替代週期。拉克利夫表示，公司在光子計數 CT 方面的潛在管道 “遠超 1 億美元”，並預計在 2026 年下半年及 2027 年實現收入轉化。</p>
</div><p>Saccaro said new products are expected to support margin improvement because they generally carry higher prices and lower costs than predecessor products. He also cited lean operating improvements through Heartbeat and general cost discipline as contributors to longer-term margin opportunity.</p>
<div class="lb-trans"><p>薩卡羅表示，預計新產品將支持利潤改善，因為它們通常比前代產品價格更高、成本更低。他還提到通過心跳管理系統的精益運營改進和一般成本控制將有助於長期利潤機會。</p>
</div><h2>China and Flircado Progress</h2>
<div class="lb-trans"><h2>中國和 Flircado 的進展</h2>
</div><p>Saccaro said GE HealthCare has made changes in China, including bringing in Will Song as leader, with a focus on commercial execution, government affairs and targeting market segments. He said the company is improving win rates and seeing a more constructive economic backdrop, though it has not changed its expectation that China will be down.</p>
<div class="lb-trans"><p>薩卡羅表示，通用電氣醫療在中國進行了變革，包括引入 Will Song 作為領導者，專注於商業執行、政府事務和市場細分。他表示，公司正在提高勝率，並看到更具建設性的經濟背景，儘管並未改變對中國市場下滑的預期。</p>
</div><p>Rackliffe said sentiment in China has stabilized and noted GE HealthCare’s large footprint in the country, including thousands of employees and multiple manufacturing plants.</p>
<div class="lb-trans"><p>拉克利夫表示，中國的情緒已經穩定，並指出通用電氣醫療在該國的大規模佈局，包括數千名員工和多個製造工廠。</p>
</div><p>Saccaro also said Flircado has made progress, with its annual run rate rising from about $25 million to roughly $46 million one quarter later. He reiterated the company’s focus on reaching more than $500 million in revenue by 2028, while emphasizing that adoption will be managed carefully to ensure customers have a positive experience.</p>
<div class="lb-trans"><p>薩卡羅還表示，Flircado 取得了進展，其年運行率從約 2500 萬美元上升到一個季度後大約 4600 萬美元。他重申公司在 2028 年前實現超過 5 億美元收入的目標，同時強調採用將謹慎管理，以確保客户獲得積極體驗。</p>
</div><p>He said the company is working through reimbursement, radiopharmacy manufacturing workflow and customer-site adoption as key factors in the launch.</p>
<div class="lb-trans"><p>他説公司正在處理報銷、放射藥學製造工作流程和客户現場採用等關鍵因素，以推動產品上市。</p>
</div><p>Looking ahead, Saccaro said GE HealthCare expects higher order growth through the rest of the year and continues to target mid-single-digit sales growth over the medium term. He said the company remains focused on innovation and operating execution while navigating a volatile cost environment.</p>
<div class="lb-trans"><p>展望未來，薩卡羅表示，GE HealthCare 預計在今年剩餘時間內訂單增長將更高，並繼續瞄準中個位數的中期銷售增長。他表示，公司仍專注於創新和運營執行，同時應對波動的成本環境。</p>
</div><h2>About GE HealthCare Technologies NASDAQ: GEHC</h2>
<div class="lb-trans"><h2>關於 GE HealthCare Technologies NASDAQ: GEHC</h2>
</div><p>GE HealthCare Technologies NASDAQ: GEHC is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.</p>
<div class="lb-trans"><p>GE HealthCare Technologies NASDAQ: GEHC 是一家全球醫療技術和診斷公司，開發、製造和銷售廣泛的產品和服務，服務於醫療保健提供者。其產品組合以診斷成像系統為中心，包括 MRI、CT、PET 和 X 射線設備，以及超聲設備。該公司還提供患者監護和麻醉輸送系統、介入和外科成像解決方案，以及用於臨牀護理和研究環境的分子成像技術。</p>
</div><p>In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.</p>
<div class="lb-trans"><p>除了硬件，GE HealthCare 還提供軟件、分析和生命週期服務，旨在改善臨牀工作流程和設備正常運行時間。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GE HealthCare Technologies Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 GE HealthCare Technologies 嗎？</h2>
</div><p>Before you consider GE HealthCare Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 GE HealthCare Technologies 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GE HealthCare Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 GE HealthCare Technologies 並不在名單上。</p>
</div><p>While GE HealthCare Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 GE HealthCare Technologies 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

GE HealthCare Technologies Sticks to Growth Story After Inflation-Driven Guidance Cut

Market Beat

GE HealthCare Tech

GE航空航天

美國銀行

霍尼韋爾

諾和諾德公司

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Honeywell International - WI

GE HealthCare Technologies 在因通脹導致指導下調後仍堅持其增長故事